We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: tirzepatide
MedXY News
EnglishTag

tirzepatide

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Comparative 1-Year Outcomes of Semaglutide, Tirzepatide, and Sleeve Gastrectomy in Obese Adults with Type 2 Diabetes: Insights from Real-World Data
Diabetes & Endocrinologyglycaemic controlobesity

Comparative 1-Year Outcomes of Semaglutide, Tirzepatide, and Sleeve Gastrectomy in Obese Adults with Type 2 Diabetes: Insights from Real-World Data

By MedXY|Jun 20, 2026

A retrospective cohort study evaluating 1-year weight loss, glycaemic control, and safety outcomes among adults with obesity and type 2 diabetes treated with semaglutide, tirzepatide, or sleeve gastrectomy, highlighting higher efficacy with

Tirzepatide vs Dulaglutide: New Post Hoc SURPASS-CVOT Data Point to Broader Cardiorenal Benefit
Cardiology
cardiorenal outcomes
dulaglutide

Tirzepatide vs Dulaglutide: New Post Hoc SURPASS-CVOT Data Point to Broader Cardiorenal Benefit

By MedXY|Jun 19, 2026

Post hoc SURPASS-CVOT analysis found tirzepatide lowered a broad 6-component cardiorenal composite versus dulaglutide in high-risk patients with type 2 diabetes, with more gastrointestinal adverse events but similar overall safety.

Tirzepatide Produced Broad 72-Week Improvements in Cardiovascular Risk Biomarkers Across Inflammatory, Metabolic, Endothelial, and Thrombotic Pathways in Obesity
Cardiologycardiovascular biomarkersobesity

Tirzepatide Produced Broad 72-Week Improvements in Cardiovascular Risk Biomarkers Across Inflammatory, Metabolic, Endothelial, and Thrombotic Pathways in Obesity

By MedXY|Jun 10, 2026

In a SURMOUNT-1 post hoc analysis, tirzepatide improved multiple cardiovascular risk biomarkers over 72 weeks in obesity, with the largest and most consistent effects seen for inflammation, insulin resistance, adiposity-related markers, end

An Obesity Subphenotype With Low Endogenous GLP-1 Production Shows Markedly Greater Weight Loss With Tirzepatide
Diabetes & Endocrinologygastric emptyingGLP-1

An Obesity Subphenotype With Low Endogenous GLP-1 Production Shows Markedly Greater Weight Loss With Tirzepatide

By MedXY|Jun 9, 2026

A 2026 study identifies a biologically distinct obesity subphenotype marked by fast gastric emptying, low GLP-1 synthesis, and substantially greater 6-month weight loss with tirzepatide.

Two-Year SURPASS-EARLY Findings Show Tirzepatide Outperforms Intensified Conventional Care in Early Type 2 Diabetes
Diabetes & EndocrinologyHbA1ctirzepatide

Two-Year SURPASS-EARLY Findings Show Tirzepatide Outperforms Intensified Conventional Care in Early Type 2 Diabetes

By MedXY|May 30, 2026

In adults with early type 2 diabetes inadequately controlled on metformin, tirzepatide produced greater 2-year reductions in HbA1c, body weight, and waist circumference than intensified conventional care, with substantially higher rates of

Tirzepatide Versus Intensified Conventional Care After 2 Years in Early Type 2 Diabetes
Diabetes & EndocrinologyHbA1ctirzepatide

Tirzepatide Versus Intensified Conventional Care After 2 Years in Early Type 2 Diabetes

By MedXY|May 30, 2026

In early type 2 diabetes uncontrolled on metformin, tirzepatide produced greater 2-year reductions in HbA1c, weight, and waist circumference than intensified conventional care, with more patients achieving normoglycemia.

Tirzepatide vs dulaglutide: kidney outcomes in type 2 diabetes from SURPASS-CVOT
Diabetes & Endocrinologyalbuminuriachronic kidney disease

Tirzepatide vs dulaglutide: kidney outcomes in type 2 diabetes from SURPASS-CVOT

By MedXY|May 12, 2026

In a pre-specified exploratory analysis of SURPASS-CVOT, tirzepatide reduced major kidney events versus dulaglutide in people with type 2 diabetes and cardiovascular disease, mainly by lowering new macroalbuminuria and slowing eGFR decline.

Tirzepatide and the Future of MASH Treatment: Insights from the SYNERGY-NASH Trial
Diabetes & Endocrinologyliver fibrosisMASH

Tirzepatide and the Future of MASH Treatment: Insights from the SYNERGY-NASH Trial

By MedXY|Jan 10, 2026

The SYNERGY-NASH trial demonstrates that Tirzepatide significantly improves MASH resolution and liver fibrosis. This effect is driven by substantial weight loss, improved glycemic control, and liver fat normalization, highlighting a transfo

Obesity as a Chronic Condition: Weight Regain Following Tirzepatide Withdrawal Reverses Vital Cardiometabolic Gains （SURMOUNT-4 trail）
Cardiologycardiometabolic healthobesity management

Obesity as a Chronic Condition: Weight Regain Following Tirzepatide Withdrawal Reverses Vital Cardiometabolic Gains （SURMOUNT-4 trail）

By MedXY|Jan 2, 2026

A post hoc analysis of the SURMOUNT-4 trial reveals that withdrawing tirzepatide leads to significant weight regain and a proportional reversal of improvements in blood pressure, glycemic control, and lipid profiles, reinforcing the necessi

Tirzepatide Shows Unprecedented Weight Loss and Reduced Insulin Demand in Adults with Type 1 Diabetes and Obesity
Diabetes & Endocrinologyinsulin sensitivityobesity

Tirzepatide Shows Unprecedented Weight Loss and Reduced Insulin Demand in Adults with Type 1 Diabetes and Obesity

By MedXY|Dec 30, 2025

A Phase 2 trial demonstrates that tirzepatide significantly reduces body weight, HbA1c, and total daily insulin requirements in adults with type 1 diabetes and obesity, offering a promising therapeutic strategy for managing metabolic health

Tirzepatide Achieves Cardiovascular Noninferiority Against Dulaglutide: A Milestone in Dual Incretin Therapy
Cardiologycardiovascular outcomestirzepatide

Tirzepatide Achieves Cardiovascular Noninferiority Against Dulaglutide: A Milestone in Dual Incretin Therapy

By MedXY|Dec 18, 2025

The SURPASS-CVOT trial confirms that tirzepatide is noninferior to dulaglutide for cardiovascular safety in high-risk type 2 diabetes patients. While superiority was not statistically reached, the study solidifies the cardiovascular profile

Tirzepatide Lowers 10‑Year Predicted Risk of Cardiovascular Disease and Type 2 Diabetes in Adults with Obesity and Prediabetes: Post hoc Analysis of SURMOUNT‑1
Cardiologycardiometabolic riskobesity

Tirzepatide Lowers 10‑Year Predicted Risk of Cardiovascular Disease and Type 2 Diabetes in Adults with Obesity and Prediabetes: Post hoc Analysis of SURMOUNT‑1

By MedXY|Dec 5, 2025

A post hoc analysis of the three‑year SURMOUNT‑1 trial found that once‑weekly tirzepatide (5–15 mg) produced dose‑dependent reductions in 10‑year predicted risks for ASCVD, heart failure, total CVD and progression to type 2 diabetes versus

Efficacy and Safety of Tirzepatide Added to Basal Insulin in Chinese Patients with Type 2 Diabetes: Insights from the SURPASS-CN-INS Phase 3 Trial
Diabetes & Endocrinologybasal insulinChina

Efficacy and Safety of Tirzepatide Added to Basal Insulin in Chinese Patients with Type 2 Diabetes: Insights from the SURPASS-CN-INS Phase 3 Trial

By MedXY|Nov 17, 2025

This phase 3 study demonstrates that adding tirzepatide to basal insulin significantly improves glycemic control in Chinese patients with type 2 diabetes, with a manageable safety profile.

Tirzepatide Produces Large Real‑World Weight Loss in Women with PCOS
Diabetes & EndocrinologyobesityPCOS

Tirzepatide Produces Large Real‑World Weight Loss in Women with PCOS

By MedXY|Nov 13, 2025

A large retrospective real‑world cohort (n=4241) of women with PCOS and overweight/obesity treated with tirzepatide experienced mean 18.8% weight loss at 10 months (90% lost ≥10%); digital engagement amplified outcomes. The data are promisi

Comparative Efficacy and Safety of Tirzepatide, Semaglutide, and Liraglutide for Obesity Management: A Critical Review of Recent Cochrane Evidence
Diabetes & EndocrinologyGLP-1 receptor agonistsliraglutide

Comparative Efficacy and Safety of Tirzepatide, Semaglutide, and Liraglutide for Obesity Management: A Critical Review of Recent Cochrane Evidence

By MedXY|Oct 31, 2025

This article critically compares the efficacy, safety, and long-term outcomes of tirzepatide, semaglutide, and liraglutide for the treatment of obesity based on recent Cochrane systematic reviews, highlighting differences in weight loss, ad

Tirzepatide Shows Promising Efficacy and Safety in Managing Youth-Onset Type 2 Diabetes: Insights from the SURPASS-PEDS Trial
Diabetes & EndocrinologyGLP-1 receptor agonistpediatric endocrinology

Tirzepatide Shows Promising Efficacy and Safety in Managing Youth-Onset Type 2 Diabetes: Insights from the SURPASS-PEDS Trial

By MedXY|Oct 10, 2025

The phase 3 SURPASS-PEDS trial demonstrates that tirzepatide significantly improves glycaemic control and reduces BMI in children and adolescents with type 2 diabetes, with a safety profile consistent with adult studies.

Clinical Updatestirzepatidetype 2 diabetes

Tirzepatide Influences Muscle Composition Favorably Amid Weight Loss in Type 2 Diabetes: Insights from SURPASS-3 MRI Substudy

By MedXY|Oct 8, 2025

In type 2 diabetes patients, tirzepatide treatment led to significant reductions in muscle fat infiltration and adaptive decreases in muscle volume over 52 weeks, suggesting beneficial effects on muscle health concurrent with weight loss.

Tirzepatide’s Efficacy in HFpEF and Obesity: Unraveling Diabetes’ Influence from the SUMMIT Trial
Cardiologyheart failure with preserved ejection fractionobesity

Tirzepatide’s Efficacy in HFpEF and Obesity: Unraveling Diabetes’ Influence from the SUMMIT Trial

By MedXY|Oct 8, 2025

The SUMMIT trial reveals that tirzepatide improves heart failure outcomes and quality of life in obese HFpEF patients with or without type 2 diabetes, despite attenuated weight loss in diabetic patients.

Early Insulin Sensitization by Tirzepatide in Japanese Patients with Obesity and Type 2 Diabetes: Insights from a Hyperinsulinaemic-Euglycaemic Clamp Study
Clinical Updatesinsulin sensitivityobesity

Early Insulin Sensitization by Tirzepatide in Japanese Patients with Obesity and Type 2 Diabetes: Insights from a Hyperinsulinaemic-Euglycaemic Clamp Study

By MedXY|Oct 8, 2025

A 12-week prospective study demonstrates tirzepatide significantly improves insulin sensitivity in obese Japanese patients with type 2 diabetes, independent of weight loss, as assessed by hyperinsulinaemic-euglycaemic clamp.

Semaglutide and Tirzepatide Significantly Reduce Hospitalization and Mortality in Cardiometabolic HFpEF Patients: Real-World Evidence
Cardiologyheart failure with preserved ejection fractionsemaglutide

Semaglutide and Tirzepatide Significantly Reduce Hospitalization and Mortality in Cardiometabolic HFpEF Patients: Real-World Evidence

By MedXY|Oct 5, 2025

Real-world analysis shows semaglutide and tirzepatide reduce hospitalization for heart failure or all-cause mortality by over 40% in patients with cardiometabolic HFpEF, with no significant difference between the two drug options.

1 / 2
12
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities